In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation...
Other content in this Stream
In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, discussing overreporting SUSARs and the impact on patient safety.
A Fresh Perspective from the FDA on the Final IND Safety Reporting Rule
WCG’s SafetyVigilance® Online Safety Event Solution Delivers Quality and Efficiency to Unify Enterprise Trial Management and Meet Regional Guidelines and Regulations
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Steven Beales and Joe O’Rourke, vice president, business development talk through some of the difficulties Sponsors face when it comes to safety letter distribution, and how to overcome them.
Roche recognized several major challenges that its CTSP 2.0 system needed to address.
Learn how a large, global pharmaceutical company saved millions of dollars by optimizing their safety reporting process.